About HaemO2
HaemO2 is a company based in United States founded in 2011. It operates as a B2B. HaemO2 has raised $184.63 thousand across 2 funding rounds from investors including IceniFund. HaemO2 operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter University, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Chennai, Tamil Nadu, India
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$184.63 K (USD)
in 2 rounds
-
Latest Funding Round
$145.95 K (USD), Grant
Aug 01, 2013
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of HaemO2
HaemO2 has successfully raised a total of $184.63K across 2 strategic funding rounds. The most recent funding activity was a Grant round of $145.95 thousand completed in August 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in HaemO2
HaemO2 has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include IceniFund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Image compression tools are provided for optimizing file sizes.
|
Locked | Locked | Locked |
Investor details for HaemO2
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HaemO2
Investment portfolio details for HaemO2
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - HaemO2
Detailed financials for HaemO2
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Haemo2 Comparisons
Peer comparison for HaemO2
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of HaemO2
HaemO2 operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of HaemO2
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Haemo2
Complete news archive for HaemO2
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HaemO2
HaemO2 was founded in 2011 and raised its 1st funding round 1 year after it was founded.
HaemO2 is headquartered in United States.
HaemO2 is a funded company, having raised a total of $184.63K across 2 funding rounds to date.
HaemO2 operates with a B2B model, focusing on providing healthcare solutions, advancing biotech innovations, developing medical devices, and blood substitutes. Develops engineered hemoglobin for creating advanced blood substitute solutions. It emphasizes efficiency, client-focused solutions, and growth, fostering partnerships and innovation in its operations.
HaemO2's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
HaemO2 has 1 investor. Key investors include IceniFund.